ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone905-842-5150
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$536.99 million
Profitability
Miscellaneous
Employees435
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Advanz Pharma (OTCMKTS:CXRXF) Frequently Asked Questions
What is Advanz Pharma's stock symbol?
Advanz Pharma trades on the OTCMKTS under the ticker symbol "CXRXF."
How were Advanz Pharma's earnings last quarter?
Advanz Pharma Corp (OTCMKTS:CXRXF) issued its earnings results on Wednesday, August, 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.03. The firm had revenue of $131.08 million for the quarter, compared to analyst estimates of $127 million. Advanz Pharma had a negative return on equity of 60.90% and a net margin of 322.43%. View Advanz Pharma's Earnings History.
When is Advanz Pharma's next earnings date?
What is the consensus analysts' recommendation for Advanz Pharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanz Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advanz Pharma.
Has Advanz Pharma been receiving favorable news coverage?
News articles about CXRXF stock have trended somewhat negative on Monday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Advanz Pharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Advanz Pharma.
Who are some of Advanz Pharma's key competitors?
Some companies that are related to Advanz Pharma include Emergent Biosolutions (EBS), Genmab A/S (GMAB), Myokardia (MYOK), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Xencor (XNCR), Cambrex (CBM) and Zai Lab (ZLAB).
What other stocks do shareholders of Advanz Pharma own?
Who are Advanz Pharma's key executives?
Advanz Pharma's management team includes the folowing people:
- Mr. Graeme Neville Duncan, CEO & Director (Age 45)
- Mr. Karl Ian Belk, Chief Operations Officer (Age 51)
- Mr. Adeel Ahmad, Chief Financial Officer (Age 45)
- Mr. Robert Sully, Gen. Counsel (Age 46)
- Mr. Paul Burden, Pres of U.K. & Ireland and Corp. Communications (Age 44)
How do I buy shares of Advanz Pharma?
Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Advanz Pharma's stock price today?
One share of CXRXF stock can currently be purchased for approximately $13.7650.
How big of a company is Advanz Pharma?
Advanz Pharma has a market capitalization of $673.25 million and generates $536.99 million in revenue each year. The company earns $1.47 billion in net income (profit) each year or $11.78 on an earnings per share basis. Advanz Pharma employs 435 workers across the globe.View Additional Information About Advanz Pharma.
What is Advanz Pharma's official website?
How can I contact Advanz Pharma?
Advanz Pharma's mailing address is 5770 HURONTARIO STREET SUITE 310, MISSISSAUGA A6, L5R 3GB. The company can be reached via phone at 905-842-5150 or via email at [email protected]
MarketBeat Community Rating for Advanz Pharma (OTCMKTS CXRXF)
MarketBeat's community ratings are surveys of what our community members think about Advanz Pharma and other stocks. Vote "Outperform" if you believe CXRXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CXRXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
